TBTherese Bartholomew Bevers

Therese Bartholomew Bevers

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Therese Bartholomew Bevers has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Figure S2 shows Kaplan-Meier cumulative incidence of invasive cancer curves, with patients categorized according to whether they had undergone excision at 6 months or not.

  • Open Access

    Supplementary Figure S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Figure S3 shows the cumulative incidence of invasive cancer or DCIS curves under each treatment strategy.

  • Open Access

    Supplementary Table S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S1 shows the baseline characteristics for all individuals eligible for the study.

  • Open Access

    Supplementary Table S2 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S2 shows the cumulative incidence of invasive cancer or DCIS by year under each treatment strategy.

  • Open Access

    Supplementary Table S4 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S4 shows points estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that used parametric standardization rather than inverse probability weighting.

  • Open Access

    Supplementary Table S3 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Table S3 shows point estimates for the cumulative incidence of invasive cancer at 5 years under each treatment strategy in a sensitivity analysis that varied the inverse probability weight truncation threshold.

  • Open Access

    Data from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance:Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.See related Spotlight, p. 555

  • Open Access

    Supplementary Figure S1 from Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    Supplementary Figure S1 is a flow diagram depicting the application of eligibility criteria used to derive the final analytic cohort.

  • Active Monitoring versus Surgical Excision for Atypical Ductal Hyperplasia

    by Melissa Rangel, Puneet Singh, Nina Tamirisa, Constance T. Albarracin, Therese B. Bevers, Leora Sarvet, Isabelle Bedrosian, Kerollos Nashat Wanis

    The recently published 2-year outcomes of the comparing an operation to monitoring, with or without endocrine therapy (COMET) trial provide evidence for the noninferiority of active monitoring of ductal carcinoma in situ (DCIS), compared with excision. These findings raise questions for the management of atypical ductal hyperplasia (ADH). To assess whether active monitoring is a safe strategy in selected patients with ADH, we used observational data on women diagnosed at an academic comprehensive cancer center and emulated a target trial of surgical excision versus active monitoring. Eligibility criteria were adapted from the COMET trial: age 40 years or older, without concurrent malignancy or a history of ipsilateral breast cancer or DCIS within the prior 5 years, without breast cancer symptoms, with no mass on physical examination or imaging, and without a history of recent endocrine therapy use. We estimated the risk of ipsilateral invasive carcinoma. There were 673 women with low-risk ADH, 238 (35.4%) of whom underwent surgical excision within 6 months. The risk of ipsilateral invasive carcinoma was 2.4% [95% confidence interval (CI), 0.8–4.1%] at 2 years with surgical excision and 0.4% (95% CI, 0–0.9%) with active monitoring (difference: 2.0; 95% CI, 0.3–3.8). At 5 years, the risk was 2.4% (95% CI, 0.8–4.2%) with surgical excision and 1.8% (0.7–3.3%) with active monitoring (difference: 0.5; 95% CI, −1.6 to 2.6). All cancers diagnosed at surgical excision or during follow-up were stage I. These findings provide evidence that active monitoring is safe and does not increase the risk of invasive carcinoma compared with surgical excision in patients with low-risk ADH. Prevention Relevance: Surgical excision is commonly performed for ADH of the breast. This study found that women with low-risk ADH had a very low risk of invasive cancer with active monitoring, which was similar to the risk under surgical excision. The findings support omission of surgery in these patients.


  • Open Access

    Using Continuous Glucose Monitoring as a Biological Feedback Strategy to Motivate Physical Activity in Cancer Survivors: A Mixed-Methods Pilot Study

    by Yue Liao, Grace E. Brannon, Chad D. Rethorst, Miranda Baum, Therese B. Bevers, Susan M. Schembre, Karen M. Basen-Engquist

    Introduction: Identifying novel strategies to motivate regular physical activity in cancer survivors continues to be a critical mission, as the majority of cancer survivors are not sufficiently active to achieve the many health benefits of being regularly physically active. Providing biological feedback is one of the behavioral change techniques that shows promising effects in physical activity interventions. This study used a mixed-methods approach to test the acceptability and changes in physical activity motivation of a pilot intervention that provided personalized feedback via text messaging based on data from an activity tracker (Fitbit) and continuous glucose monitor (CGM) over a 4-week period. Methods: Twelve breast and colorectal cancer survivors completed this pilot intervention, which involved a one-on-one educational session followed by a 4-week intervention period with a Fitbit wristband and CGM. They received 2-3 weekly text messages based on their Fitbit and CGM data that aimed to increase their motivation to engage in physical activity. Participants completed surveys assessing motivational readiness before and after the intervention, and a post-intervention survey that assessed acceptability of the intervention. Exit interview was also conducted to collect their feedback and opinions toward the intervention. Results: Both quantitative and qualitative results suggest a high acceptability of the study devices (ie, Fitbit and CGM) as well as the intervention components (e.g., the glucose-based biological feedback). Participants reported a significant decrease in the preparation stage and an increase in the action and maintenance stages (ps < 0.05). Results from qualitative analysis further indicate participants’ positive changes in physical activity motivations. Conclusion: The use of CGM along with an activity tracker is a viable method to provide personally relevant and motivating biological feedback messages to motivate physical activity in cancer survivors. Future studies can incorporate this behavior change technique into their intervention and further evaluate its impact on behavior change and related health outcomes. Clinical trial number: NCT05124405.